Study of ATG-022 plus pembrolizumab for stomach or GEJ cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor tests positive for CLDN 18.2 and PD-L1, and negative for HER2.
- You have at least one tumor that can be measured on scans.
- You have not had prior treatment with CLDN 18.2-targeted drugs or certain other therapies within the last 4 weeks.
- You have not had severe side effects from a previous immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy (FLOT) for people with advanced stomach or gastroesophageal junction cancer. It may help if your cancer has not been treated before and you are in reasonably good health.
This trial tests a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as a first treatment for people with advanced or metastatic stomach or gastroesophageal junction cancer. It's looking for patients whose tumors have a specific protein called CLDN18.2, and who have not had prior treatment for advanced disease.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
Hear when a new Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.